Our Executive Director, Alex Filicevas, recently sat down with Dr Ashish Kamat, MD, Chair of the WBCPC Scientific Advisory Board, for a conversation with UroToday and GU OncToday at the American Urological Association Annual Meeting (AUA2026) in Washington DC. Together, they discussed new findings from the recently published Bladder Cancer Burden Survey, and what the data reveals about the real impact of bladder cancer treatment on the lives of patients.
Today, our Executive Director, Alex Filicevas, co-moderated a high-level event at the European Parliament in Brussels, hosted by All.Can International. The event brought together Members of the European Parliament, health system experts, researchers, and patient advocates to address a question that sits at the heart of our work: what does it actually take to make cancer care work for the person receiving it?
The timing could not have been more important.
Bladder cancer is more than a clinical diagnosis. For the people living with it, it is years of treatment, repeated check-ups and a quiet emotional weight that shapes everyday life in ways rarely captured in the clinic.
On May 14, our Executive Director, Alex Filicevas, joined a panel discussion at in Washington, D.C., held ahead ofthe American Urological Association (AUA) Annual Meeting 2026. The panel brought patient advocates, clinicians and researchers together to discuss findings from a new global survey on how current standard-of-care treatments for non-muscle-invasive bladder cancer (NMIBC) affect patients’
Today, at the Biosimilar Medicines Conference 2026 in Amsterdam, our Executive Director, Alex Filicevas, spoke on behalf of the bladder cancer patient community during the session “EU Biosimilar Strategy: Synergies between Horizon Scanning and Capacity Building”.
Organised by Medicines for Europe, the conference brought together all interested stakeholders from across Europeand beyond to discuss the future of biosimilar medicines and how they can help improve access for patients and strengthen healthcare systems.
Bladder Cancer Awareness Month (BCAM) 2026 is approaching and this year carries particular importance.
It marks the final year of the global “Feeling unsure? Get checked.” campaign, a three-year effort focused on one critical issue: people often hesitate to seek medical advice when they notice potential symptoms, especially blood in the urine.
This hesitation can delay diagnosis and affect outcomes. Yet early detection makes a real difference.
At the Cancer Drug Development Forum (CDDF) Workshop 2026, held on March 30, 2026, in Brussels, Belgium, our Executive Director, Alex Filicevas, spoke during the session “Challenges in the Landscape of a Global Development Strategy, including patient access”, focusing on the role of patient-reported outcomes (PROs) in cancer clinical trials.
PROs are used in clinical trials to capture how patients feel during and after treatment. They provide important insight into symptoms,
At the European Association of Urology Congress 2026 (EAU26), the session “Closing the diagnostic and care gaps for women with urinary cancers and conditions” explored the persistent disparities affecting women with bladder cancer and the actions needed to address them.
The session was moderated by Michelle Colero, our Vice President and Executive Director of Bladder Cancer Canada, who presented the patient advocacy perspective and highlighted the gender inequalities that continue to affect women across the bladder cancer care pathway.
